Pharmacogenomics (PGx) Tacrolimus CYP3A5 Test
A targeted pharmacogenomic test evaluating CYP3A5 metabolizer status to optimize tacrolimus dosing for transplant patients, powered by the Helix Exome+® platform.
Turnaround
6-9 days
Requery (SOQO)
≤ 5 minutes
Genes Tested
1
Panel Description
Tacrolimus is an immunosuppressant prescribed to patients undergoing organ transplant to reduce risk of organ rejection. Tacrolimus reduces activity of the immune system, leading to reduced risk of organ rejection, specifically for adult patients who have received a kidney, liver, lung, or heart transplant. This drug may also be prescribed to children undergoing organ transplant under specific clinical circumstances.
Order This Test
Contact our clinical team to order this panel or learn more.
Indications for Testing
Providing a genetic evaluation to determine whether oral use of tacrolimus can reduce risk of organ rejection for transplant patients.
Methodology
This test utilizes next-generation sequencing to determine star alleles and metabolizer status for CYP3A5. These results are used to determine drug considerations for Tacrolimus.
Technical Specifications
Reportable range
CYP3A5: *1, *3, *6-*9
Genes Tested
1 genes included in this panel
Ordering Information
Turnaround Time
Typically 6-9 days (standard), Typically ≤ 5 minutes (requery)
Preferred Specimen
BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit
Shipping Instructions
Specimens to arrive at Helix within 96 hours of collection at ambient temperature.
Clinical Description
Tacrolimus is an immunosuppressant prescribed to patients undergoing organ transplant to reduce risk of organ rejection. Tacrolimus reduces activity of the immune system, leading to reduced risk of organ rejection, specifically for adult patients who have received a kidney, liver, lung, or heart transplant. This drug may also be prescribed to children undergoing organ transplant under specific clinical circumstances.
This test evaluates a patient’s metabolizer status for CYP3A5, which can aid in optimal dosing of tacrolimus to maximize immune suppression efficacy to prevent organ rejection and reduce risk of side effects for transplant patients.
Ready to order this test?
Contact our clinical team to order the Pharmacogenomics (PGx) Tacrolimus CYP3A5 Test for your patients.